« Return to News | Awards & Advancement

Alliance for Biosecurity elects new co-chairs

Wednesday, July 3, 2013 02:24 PM

The Alliance for Biosecurity, a collaboration among pharmaceutical and biotechnology companies, has elected Anders Hedegaard, president and chief executive officer of vaccine-focused biotechnology Bavarian Nordic, and Elizabeth Posillico, Ph.D., president and chief executive officer of antibody therapeutics developer Elusys Therapeutics, its new co-chairs.

They will represent the Alliance before the U.S. government and other agencies to advance the development of new medical countermeasures to be used against chemical, biological, radiological and nuclear threats. Hedegaard and Posillico will each serve a two-year term, which began in June.

The Alliance for Biosecurity was formed in 2005 to improve the nation's biosecurity through the development of medical countermeasures (MCMs) to address bioterrorism and natural pandemic threats. Activities of the Alliance include educating Congress and other government stakeholders about biosecurity and drug development issues, promoting the success of the Biomedical Advanced Research and Development Authority (BARDA), advancing the science of animal model development, accelerating MCM development and presenting consensus policy proposals.

The Alliance has successfully advocated for preserving the BioShield Special Reserve Fund and BARDA to maintain funding for the development and procurement of MCMs.  In addition, several Alliance recommendations for enhancing the regulatory pathway for MCMs and integrating the FDA into the development process were adopted in recently enacted legislation.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.